David Lally, MD
Ophthalmology · Springfield, MANPI 1457686586
Payments from drug & device makers
Across 435 payments — averaging $10,356 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2.3M
- Apellis Pharmaceuticals, Inc.$1.6M
- Genentech, Inc.$168K
- Eyepoint US, Inc.$118K
- AstraZeneca$74K
- Genentech USA, Inc.$66K
- plus $194K from 19 others
Across 6 payments — averaging $6107.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$22K
- Canon Inc.$14K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 78 | $2,263,737 |
| Apellis Pharmaceuticals, Inc. | 47 | $1,620,946 |
| Genentech, Inc. | 38 | $167,879 |
| Eyepoint US, Inc. | 11 | $118,253 |
| AstraZeneca | 4 | $74,370 |
| Genentech USA, Inc. | 54 | $65,673 |
| Astellas Pharma Global Development | 11 | $39,371 |
| Regeneron | 22 | $37,816 |
| Alimera Sciences, Inc. | 42 | $31,105 |
| Regeneron Healthcare Solutions, Inc. | 21 | $23,597 |
| AbbVie(2 entities) | 41 | $21,603 |
| Boehringer Ingelheim International GmbH | 8 | $16,826 |
| Ocular Therapeutix, Inc. | 11 | $7,727 |
| Boehringer Ingelheim | 1 | $4,750 |
| F. Hoffmann-la Roche AG | 2 | $4,648 |
| Astellas Pharma US Inc | 12 | $3,186 |
| Neurotech Pharmaceuticals, Inc. | 2 | $2,113 |
| Notal Vision, Inc. | 20 | $669 |
| Alcon | 2 | $356 |
| Coherus Oncology, Inc. | 3 | $93 |
| Harrow Eye, LLC | 1 | $32 |
| Biogen | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
How this compares
$4,504,818 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Springfield
- Shilpa GulatiSpringfield$422K
- Gail TorkildsenAndover$5.1M
- Jennifer SunBoston$4.2M
- Lloyd AielloBoston$3.1M
- Rishi SinghBoston$2.5M
- Rachel HuckfeldtStoneham$1.7M
- Mark AbelsonAndover$1.3M
- Peter ChangWaltham$1M
- Stephen AnesiWaltham$922K
- Charles FosterWaltham$888K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.